US 11,884,746 B2
Matriptase and u-plasminogen activator substrates and other cleavable moieties and methods of use thereof
Stephen James Moore, Danville, CA (US); Margaret Thy Luu Nguyen, San Francisco, CA (US); Daniel Robert Hostetter, Palo Alto, CA (US); and Olga Vasiljeva, Cupertino, CA (US)
Assigned to CytomX Therapeutics, Inc., South San Francisco, CA (US)
Filed by CytomX Therapeutics, Inc., South San Francisco, CA (US)
Filed on Apr. 26, 2021, as Appl. No. 17/240,278.
Application 17/240,278 is a division of application No. 16/160,846, filed on Oct. 15, 2018, granted, now 11,028,126.
Application 15/390,975 is a division of application No. 14/610,468, filed on Jan. 30, 2015, granted, now 9,562,073, issued on Feb. 7, 2017.
Application 16/160,846 is a continuation of application No. 15/390,975, filed on Dec. 27, 2016, granted, now 10,138,272, issued on Nov. 27, 2018.
Claims priority of provisional application 61/971,009, filed on Mar. 27, 2014.
Claims priority of provisional application 61/934,619, filed on Jan. 31, 2014.
Prior Publication US 2022/0411470 A1, Dec. 29, 2022
Int. Cl. C07K 7/06 (2006.01); A61K 47/65 (2017.01); A61K 47/68 (2017.01); C07K 7/08 (2006.01); C07K 16/00 (2006.01); A61K 49/00 (2006.01); C07K 16/28 (2006.01); A61K 39/00 (2006.01)
CPC C07K 7/06 (2013.01) [A61K 47/65 (2017.08); A61K 47/6803 (2017.08); A61K 47/6835 (2017.08); A61K 47/6889 (2017.08); A61K 49/0056 (2013.01); C07K 7/08 (2013.01); C07K 16/00 (2013.01); C07K 16/2809 (2013.01); C07K 16/2863 (2013.01); A61K 2039/505 (2013.01); C07K 2317/54 (2013.01); C07K 2317/55 (2013.01); C07K 2317/569 (2013.01); C07K 2317/622 (2013.01); C07K 2317/92 (2013.01); C07K 2319/50 (2013.01)] 6 Claims
 
1. A method of manufacturing an activatable molecule that contains a cleavable moiety (CM) that is a substrate for a matriptase, the method comprising expressing and recovering an isolated polypeptide comprising a CM amino acid sequence of LSGRSANH (SEQ ID NO: 307), wherein said CM amino acid sequence is the substrate for the matriptase.